Skip to content

Coherus Neulasta biosimilar loses preferred status at Express Scripts

August 20, 2020

Coherus BioSciences (CHRS -2.6%) slips on below-average volume in apparent reaction to the exclusion of Udencya (pegfilgrastim-cbqv), a biosimilar to Amgen’s (AMGN -0.8%) Neulasta, from Express Scripts’ 2021 preferred formulary that goes into effect January 1.

The pharmacy benefit manager’s preferred Neulasta biosimilars for next year are Mylan’s (MYL -0.9%) Fulphila (pegfilgrastim-jmdb) and Novartis’ (NVS +1.9%) Ziextenzo (pegfilgrastim-sndz).

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: